SAB Biotherapeutics, Inc., (SABS) Social Stream
SAB BIOTHERAPEUTICS INC (SABS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering SABS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-23 | 4 | $23 | $16.5 | $18.625 | $0.469 | 3871.22% |
| 2021-12-02 | 4 | $23 | $16.5 | $19.375 | $0.469 | 4031.13% |
| 2022-03-31 | 4 | $23 | $9 | $16.375 | $0.469 | 3391.47% |
| 2022-04-04 | 4 | $23 | $9 | $14.625 | $0.469 | 3018.34% |
| 2022-04-06 | 4 | $23 | $9 | $14.1 | $0.469 | 2906.4% |
| 2022-05-15 | 4 | $23 | $7 | $13.35 | $0.469 | 2746.48% |
| 2022-05-17 | 4 | $23 | $7 | $12.85 | $0.469 | 2639.87% |
| 2022-08-11 | 4 | $12.4 | $3 | $7.1 | $0.469 | 1413.86% |
| 2022-08-23 | 3 | $9 | $3 | $6.062 | $0.469 | 1192.54% |
| 2022-11-16 | 2 | $9 | $3 | $6.062 | $0.469 | 1192.54% |
| 2022-11-21 | 3 | $9 | $3 | $5.75 | $0.469 | 1126.01% |
| 2023-01-18 | 3 | $9 | $3 | $5.4 | $0.469 | 1051.39% |
The Trend in the Analyst Price Target
SABS's average price target has moved down $0.66 over the prior 63 days.
SABS reports an average of 483.26% for its upside potential over the past 42 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-31 | 4 | 23 | 9 | 16.375 | 3.760 | 335.51% |
| 2022-04-06 | 4 | 23 | 9 | 14.100 | 2.650 | 432.08% |
| 2022-08-23 | 3 | 9 | 3 | 6.062 | 0.945 | 541.48% |
| 2022-11-16 | 2 | 9 | 3 | 6.062 | 1.050 | 477.33% |
| 2022-11-21 | 2 | 9 | 3 | 5.750 | 1.090 | 427.52% |
SABS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
Over the past 35 weeks, SABS's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SABS as an investment opportunity.
- SABS has a higher upside potential (average analyst target price relative to current price) than 1371.33% of all US stocks.
- In terms of how SAB BIOTHERAPEUTICS INC fares relative to all US stocks, note that its average analyst price target is higher than 169.4% of that group.
- To contextualize these metrics, consider that out of Healthcare stocks, SAB BIOTHERAPEUTICS INC's number of analysts covering the stock is greater than 207.22% of them.
- SABS has a lower variance in analysts' estimates than -1017.02% of stocks in the small market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to SAB BIOTHERAPEUTICS INC are GRNA, VOR, and FNCH.
View All Top Stocks by Price Target
Make investment decisions regarding SABS using the data that counts. Try POWR Ratings for free.